Kornimate/medical-research-clean huggingface dataset:
bronchoalveolar immune response determination

Conditions: Extrinsic Allergic Alveolitis

Summary: the purpose of this study is to establish if cells present in lung tissue during extrinsic allergic alveolitis (eaa) are able to elicit an immune response against specific antigens. the hypothesis is: cells in bal lavage fluid from patients with eaa will be responsive to specific antigens and this response can be measured using elispot.

subjects suffering from extrinsic allergic alveolitis caused by pigeons will undergo a broncho alveolar lavage. cells obtained from this bal will be used for elispot technique with pigeon specific antigens

Eligibility criteria:
inclusion criteria: * suspicion of pigeon induced extrinsic alveolitis exclusion criteria: * use of oral steroids * unable to give informed consent * age below 18

Keywords: pigeon bird fancier extrinsic allergic alveolitis bal broncho-alveolar lavage elispot antigen
study of botulinum toxin type a for the treatment of patients with idiopathic overactive bladder with urinary incontinence

Conditions: Overactive Bladder

Summary: the purpose of this study is to assess the safety and effectiveness of botulinum toxin type a (onabotulinumtoxina) in treating patients with idiopathic overactive bladder with urinary incontinence.


Eligibility criteria:
inclusion criteria: * symptoms of oab (frequency/urgency) with urinary incontinence for at least 6 months * inadequate response or limiting side effects with anticholinergics for the treatment of oab exclusion criteria: * overactive bladder caused by neurological condition * patient has predominance of stress incontinence * history or evidence of pelvic or urological abnormality
a study to characterize pharmacokinetics of tiotropium + olodaterol fixed-dose combination in japanese patients with copd.

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the primary objective of this study is to assess pharmacokinetics of tiotropium + olodaterol fixed-dose combination (2.5 µg/ 5 µg, 5 µg/ 5 µg) delivered by the respimat inhaler after 3 weeks once daily treatment in japanese patients with copd.


Eligibility criteria:
inclusion criteria: 1. diagnosis of chronic obstructive pulmonary disease 2. relatively stable airway obstruction with post fev1=\<30% of predicted normal and\< 80% predicted normal and post fev1/fvc \<70% 3. male or female japanese patients, 40 years of age or older 4. smoking history of more than 10 pack years exclusion criteria: 1. significant disease other than copd 2. clinically relevant abnormal lab values 3. history of asthma 4. diagnosis of thyrotoxicosis 5. diagnosis of paroxysmal tachycardia 6. a marked baseline prolongation of qt/qtc interval 7. a history of additional risk factors for torsade de pointes (tdp) 8. history of myocardial infarction within 1 year of screening visit 9. unstable or life-threatening cardiac arrhythmia 10. hospitalization for heart failure within the past year 11. known active tuberculosis 12. malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years 13. history of life-threatening pulmonary obstruction 14. history of cystic fibrosis 15. clinically evident bronchiectasis 16. history of significant alcohol or drug abuse 17. thoracotomy with pulmonary resection 18. oral ß-adrenergics 19. oral corticosteroid medication at unstable doses 20. regular use of daytime oxygen therapy for more than one hour per day 21. pulmonary rehabilitation program in the six weeks prior to the screening visit 22. investigational drug within one month or six half lives (whichever is greater) prior to screening visit 23. known hypersensitivity to ß-adrenergic drugs, anticholinergics, bac, edta 24. pregnant or nursing women 25. women of childbearing potential not using a highly effective method of birth control 26. patients who have previously been randomized in this study or are currently participating in another study 27. patients who are unable to comply with pulmonary medication restrictions 28. patients with narrow-angle glaucoma or micturition disorder due to prostatic hyperplasia etc 29. patients being treated with medications that prolong the qt/qtc interval
validation of the utility of ophthalmology intelligent diagnostic system

Conditions: Ophthalmopathy; Artificial Intelligence

Summary: the prevention and treatment of diseases via artificial intelligence represents an ultimate goal in computational medicine. application scenarios of the current medical algorithms are too simple to be generally applied to real-world complex clinical settings. here, the investigators use "deep learning" and "visionome technique", an novel annotation method for artificial intelligence in medical, to create an automatic detection and classification system for four key clinical scenarios: 1) mass screening, 2) comprehensive clinical triage, 3) hyperfine diagnostic assessment, and 4) multi-path treatment planning. the investigator also establish a telemedicine system and conduct clinical trial and website-based study to validate its versatility.


Eligibility criteria:
inclusion criteria: * patients and residents who underwent ophthalmic examination of the eye and recorded their ocular information in the outpatient clinic and community.

Keywords: conjunctivitis keratitis pterygium cataracts
safety/tolerability and efficacy of yhd001 in patients with acute and chronic bronchitis

Conditions: Acute Bronchitis; Chronic Bronchitis

Summary: the study will conduct with 4 comparative groups orally treated with yhd001 dose level 1(t.i.d.), yhd001 dose level 2(t.i.d.), pelargonium sidoides extract 9ml(t.i.d.) or placebo for 7 days. the treatments will be assigned randomly to patients (n=116) with acute or chronic bronchitis.

the outcome measures is to evaluate the overall change from baseline to the end of treatment in scores relating to the severity of four symptom of bronchitis: cough, sputum, qol of daily life, qol of falling asleep at night.

Eligibility criteria:
inclusion criteria: * male and female patients aged ≥18 year * provision of written informed consent * acute bronchitis with a bronchitis severity score(bss)≥five points exclusion criteria: * history of any clinically significant disease * history of drug/chemical/alcohol abuse * use of antibiotics, anti-histamine during the 7 days before administration of the investigational product
towards an early integration of palliative care in oncology

Conditions: Metastatic Cancer; Palliatives Treatments

Summary: the primary objective of the study is to describe the nature and to estimate the prevalence the health needs of patients with metastatic cancer and their main caregivers, between the period from diagnosis to death. as secondary objectives, the study aims: * to determinate the proportion of patients with an indication for palliative care according to hui et al., and to describe the adequation of health needs and the services for them; * to study the association between clinical pathway and the indication of targeted palliative care; * to study the association between the integration of palliative care service and the adequation of health needs service of patients; * to study the factors such as the disease, the practice and the care, contribute to the patient's survivor of 1 year.

this is a descriptive, transversal, multicenter study, which will be performed in healthcare facilities in ile de france area. each investigator center will be composed by oncologist / palliative care and support team. 10 centers will participate to the study, enrollement will be perfomed during 6 months targetting 400 patients with advanced cancer.

Eligibility criteria:
inclusion criteria: * patients ≥ 18 years; * diagnosed metastatic cancer; * outpatient or inpatient care at a participating site to the study; * affiliation to the social security scheme; * patient informed and non-opposed to participate to the study. exclusion criteria: * testicular or choriocarcinoma ovarian cancer; * hematology cancer; * no understanding french language; * unable to express if needed his non-opposition opinion, according to physician investigator; * visually impaired, hearing impaired or aphasic.

Keywords: metastatic cancer palliative care oncology health needs early integration
prevention of neck pain in adults with a back school-based intervention.

Conditions: Neck Pain; Exercise Therapy; Health Education; Primary Prevention

Summary: the study consists of a theoretical and practical intervention based on the back school. this intervention will be carried out over 8 weeks with a frequency of two sessions per week, for a total of 16 sessions of 45 minutes duration. of all the sessions, 14 had a practical focus (strength and stretching exercises) and the other two had a theoretical focus (self-management techniques and pain neuroscience education). the clinical practice guidelines highlight the importance of neck pain prevention through exercise an education. there are previous studies of the effects of theoretical and practical programmes based on back school on the lumbar region but not on the cervical region.therefore, the main aim of this innovative study is to to investigate the effects of a back school based intervention on the prevention of neck pain and as secondary objectives to investigate the effects on neck flexor and extensor strength as well as scapular stability. the hypothesis is that this bs-based intervention would have positive effects on neck pain prevention, neck strength and scapular stability.


Eligibility criteria:
inclusion criteria: * ages 18 - 65 years old. * not have had neck pain in the last 6 months. exclusion criteria: * previous neck or shoulder surgery, cervical radiculopathy/myelopathy, history of the whiplash injury. * taking any medication or having any musculoskeletal, rheumatic, metabolic, cardiological, cognitive disorder or neurological disorder. * missing more than two back school sessions. * not being able to attend the measurement sessions.
biomarkers for circadian timing in healthy adults

Conditions: Sleep Wake Disorders; Sleep Disorders, Circadian Rhythm; Sleep Disorders, Intrinsic; Advanced Sleep Phase Syndrome (ASPS); Advanced Sleep Phase Syndrome; Advanced Sleep Phase; Delayed Sleep Phase; Delayed Sleep Phase Syndrome; Non-24 Hour Sleep-Wake Disorder; Irregular Sleep-Wake Syndrome; Shift-Work Sleep Disorder; Shift Work Type Circadian Rhythm Sleep Disorder; Delayed Phase Sleep Syndrome

Summary: study investigators want to learn more about the underlying biological clock and to see if the timing of that clock can be estimated from a single blood sample.

there is an urgent need for a practical way to assess circadian timing accurately in both general and sleep medicine. the study is designed to assess the levels of different biomarkers in the blood taken from frequent samples across three separate sleep-wake conditions - conventional/normal sleep-wake conditions (baseline), extended wake/acute sleep deprivation (constant routine), and during irregular sleep-wake conditions (inverted day). participants will be asked to complete medical, psychological, and sleep-wake evaluations prior to the study. upon completion of screening, if eligible, participants will stay 7 consecutive days and nights in the sleep research laboratory within the hospital.

Eligibility criteria:
inclusion criteria: * healthy adults with conventional and regular sleep-wake timing * non-smokers * able to spend 7 consecutive days/nights in the laboratory * willing to abstain from use of caffeine, nicotine, and alcohol during pre-study and study periods exclusion criteria: * history of neurological or psychiatric disorder * history of sleep disorder or regular use of sleep-promoting medication * current prescription, herbal, or over-the-counter medication use * traveling across 2 or more time zones within the past 3 months * donating blood within the past 8 weeks * worked night or rotating shiftwork within the past 3 years * hearing impairment * drug or alcohol dependency * pregnant, intending to become pregnant, or recently pregnant (last 6 months) * breastfeeding within the past 6 months

Keywords: sleep aging circadian rhythms circadian rhythm disorders
uterine artery embolization and pelvic floor symptoms

Conditions: Leiomyoma; Incontinence; Prolapse

Summary: the objective of this study is to determine whether women who are already receiving treatment for their fibroids (ie. uae) demonstrate improvement in urinary symptoms and sexual dysfunction as well.


Eligibility criteria:
inclusion criteria: * female * age 18-80 years * symptomatic uterine fibroids * scheduled for uae * negative urine dipstick (negative result = trace or less for leukocytes \& nitrites) or negative ua or negative culture (urine dipstick is performed as standard of care) * available for 12-months of follow-up and able to complete study assessments, per clinician judgment * signed consent form exclusion criteria: * age \ 80 years * women who are unable to read and write english, * pregnancy or planned pregnancy in the next 12 months * \< 6 months postpartum * current use of anticholinergic medication, cholinergic agonists, tricyclic antidepressants, or duloxetine - must have been off such drugs for at least 4 weeks * women with surgery for urinary incontinence or pelvic organ prolapse in the past 6 months * history of bladder or pelvic cancer or pelvic radiation therapy * prior augmentation cystoplasty * urethral diverticulum, current or repaired.
bay59-7939 in atrial fibrillation once daily (od)

Conditions: Atrial Fibrillation

Summary: this is an exploratory investigation of safety, pharmacokinetic (pk) and pharmacodynamic (pd) effects of bay59-7939 with multiple oral doses of 10 mg, 15 mg and 20 mg once daily (od) in japanese subjects with non-valvular atrial fibrillation (originally described in japanese).


Eligibility criteria:
inclusion criteria: japanese subjects with non-valvular af who met all of the following criteria: * male subjects aged 20 years or older and postmenopausal female subjects * subjects with persistent or paroxysmal non-valvular af with \>/=2 episodes before enrollment, at least 1 of which had been verified by ecg recording within 4 weeks before randomization * subjects who were at risk for stroke as follows: * subjects with at least one risk factor for thromboembolism (hypertension, diabetes mellitus, coronary artery disease, congestive heart failure). * subjects aged 60 years old and above regardless of the existence of above risk factors. exclusion criteria: * history or presence of stroke or transient ischemic attack. * history of intracerebral hemorrhage. * history or presence of bleeding at randomization; intraocular or gastrointestinal bleeding within the last 6 months prior to randomization.

Keywords: bay59-7939 rivaroxaban non-valvular atrial fibrillation japanese patients phase ii
the effects of application intervention on the physiological indicators and low protein diet cognition among the patients with chronic kidney disease

Conditions: CKD Stage 4; CKD Stage 5

Summary: the effects of application intervention on the physiological indicators and low protein diet cognition among the patients with chronic kidney disease

the low-protein diet app introduces the perceived significant efficacy of low-protein diets for patients with chronic kidney disease.

Eligibility criteria:
inclusion criteria: * aged 20 years or above and agree to participate in the research * conscious, literate and able to communicate in mandarin and taiwanese * have the ability to use vehicles * kidney disease stage is 3b as calculated by the mdrd formula from stage 5 to stage 5, he has not yet received alternative therapy and is diagnosed as a patient with chronic kidney disease by a nephrologist. exclusion criteria: * blindness * cognitive abnormalities diagnosed by a doctor as dementia or mental disorder * people who have no ability to act independently and are assisted by others in daily life * patients with nephrotic syndrome are excluded.
resting metabolic rate, fat distribution, endocrine and metabolic features in polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome

Summary: in a longitudinal, prospective and observational study, patients with pcos and controls wore the sensewear armband for 2 days. resting metabolic rati (kcal/die), total energy expenditure (met, kcal) were evaluated. ultrasonographic pelvic examinations, hirsutism score, anthropometric and menstrual pattern evaluation, hormonal profile assays, oral glucose tolerance test (ogtt) and lipid profile were performed.


Eligibility criteria:
inclusion criteria: * . pcos diagnosed according with the rotterdam consensus conference criteria exclusion criteria: * presence of a late-onset adrenal enzyme defect * significant liver or renal impairment * pregnancy and nursing * neoplasm * cardiovascular disease * other hormonal dysfunctions
the suitability of sniff dog as a tool in screening tumors

Conditions: Neoplasia

Summary: previous studies have demonstrated that sniff dogs can identify cancer patients from healthy subjects through sniffing exhaled breath air or blood or serum or urine or feces. it is hypothesized that sniff dogs may be used as a tool in screening cancer patients in health examination. trained dogs will sniff serum from participants who are attending the annual health examination to identify potential or high risk subjects, and the results will be compared with the outcome of the traditional health examination, and the high risk subjects will be followed periodically for at least five years.


Eligibility criteria:
inclusion criteria: * old than 20 years * currently without cancer diagnosed with pathological examination * allow the study team to examine his/her case history and incoming record exclusion criteria: * cancer patients with pathological diagnosis * who does not allow the study team to examine his/her case history and incoming record

Keywords: lung cancer breast cancer
methadone anesthesia for kidney transplant receptors

Conditions: Renal Failure Chronic; Surgery

Summary: intraoperative methadone or fentanyl will be administered to patients submitted to kidney transplant surgery. postoperative pain, analgesic consumption and side effects will be evaluated

despite recent developments in postoperative pain control, many patients still experience moderate or severe pain after surgery. it is estimated that severe postoperative pain occurs in 20 to 40% of surgical procedures. with the development of kidney transplant services, a better study of the intraoperative analgesia used in this procedure and its impact on the postoperative is necessary. the management of postoperative pain in renal transplant recipients is essential to improve the quality of postoperative care, and may even impact the prognosis of the renal graft. one of the strategies to improve pain control in the perioperative period is the intraoperative use of intravenous methadone, given its pharmacokinetic profile. methadone is an opioid agonist of µ receptors, it is also a glutamate antagonist by blocking the n-methyl-d-aspartate (nmda) receptor, and inhibits the reuptake of serotonin and norepinephrine. when administered in doses of 20 to 30mg, the analgesia generated by methadone can last from 24 to 36 hours. there is also evidence that the use of methadone in doses of 0.2 to 0.3 mg / kg is not associated with a higher incidence of side effects when compared to other opioids with short or intermediate duration of action, such as fentanyl, sufentanil and morphine. the aim of this study is to evaluate the effectiveness of using intraoperative methadone to reduce postoperative pain in patients undergoing kidney transplant surgery (recipients). patients will be submitted to standardized general anesthesia, and the opioid used in anesthetic induction will be methadone or fentanyl with additional boluses if necessary. after extubation, fentanyl will be installed in an intravenous analgesia pump controlled by the patient. differences between groups regarding opioid consumption, pain scores, side effects and patient satisfaction will be assessed

Eligibility criteria:
inclusion criteria: * patients over 18 years of age * with indication for kidney transplant surgery * who sign the informed consent form exclusion criteria: * patients who refuse to participate in the study * known allergy to any drug used in this protocol * presence of stage iii or iv congestive heart failure * increase in qt interval on electrocardiogram (qt\> 500 msec) * preemptive kidney transplantation (defined by transplantation in a patient who has not yet started kidney replacement therapy).
a phase i dose escalation study of synthetic hypericin in hiv-infected patients with less than 300 cd4 lymphocytes

Conditions: HIV Infections

Summary: to determine the maximum tolerated dose (mtd) of hypericin, to define the types of toxicities that may be observed, and to determine what doses of the drug are associated with improvements in virological and immunological surrogate markers of hiv infection. to determine the bioavailability of synthetic hypericin given in 2 percent benzyl alcohol solution. hypericin is unlike other drugs presently being used to treat aids patients. hypericin shows anti-hiv activity in test tube experiments.

hypericin is unlike other drugs presently being used to treat aids patients. hypericin shows anti-hiv activity in test tube experiments. each group of eight patients receives a given dose of hypericin by intravenous infusion. doses are given three times per week for 8 weeks. when all eight patients at a dose level have been entered and four of the eight patients have completed 3 weeks of therapy without evidence of dose-limiting toxicity, additional patients may begin to receive drug at the next dose level. concurrently, six patients wll participate in an oral-dosing bioavailability study. note: the initial study was stopped secondary to an mtd being reached.

Eligibility criteria:
inclusion criteria concurrent medication: allowed: * prophylaxis for pneumocystis carinii pneumonia (required for patients with cd4+ \< 200). * symptomatic treatment with analgesics, antihistamines, antiemetics, antidiarrheal agents, or other supportive therapy. * short courses (\< 10 days) with ketoconazole or fluconazole for oral candidiasis or acyclovir for herpes lesions. * topical medications such as clotrimazole troches or nystatin suspensions. concurrent treatment: allowed: * blood transfusions. patients must have hiv infection with cd+4 lymphocyte count of \< 300 cells/mm3. exclusion criteria co-existing condition: patients with the following conditions or symptoms are excluded. * kaposi's sarcoma requiring systemic therapy. concurrent medication: excluded: * continued use of opiates or drugs known to induce photosensitivity. patients with the following are excluded: * active or chronic opportunistic infection at time of study entry that required curative or suppressive therapy. * significant liver disease, orthostatic hypotension, cardiac disease, seizure disorder, lymphoma, hypotension. prior medication: excluded: * zidovudine (azt), dideoxyinosine (ddi), dideoxycytidine (ddc), interferon, other antiretroviral agents or immunomodulating drugs within 1 month prior to study entry. ribavirin within 3 months of study entry. * ganciclovir (dhpg), antimycobacterial drugs, mao inhibitors, hypertension-inducing, nephrotoxic, or hepatotoxic drugs within 14 days of entry. * cytotoxic chemotherapy within 1 month prior to study entry. active substance abuse.

Keywords: drug evaluation acquired immunodeficiency syndrome aids-related complex antiviral agents